Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Using CRISPR/Cas9 knockout systems to identify synthetic interactions with hexosamine biosynthesis and N-glycan remodelling pathway enzymes to inhibit cancer cell growth
FY 2017-18
Summary
Cancer research has shifted towards developing therapies that target multiple points of a cell, as cancer cells often adapt to treatment and develop resistance. A method of identifying multiple targets uses synthetic lethal interactions, where mutations of single genes alone are not lethal, but specific mutations together result in cell death. Previous studies on cancer cell metabolism showed that disrupting hexosamine biosynthesis and N-glycan remodelling pathways inhibit tumor growth. Little is known about how cancer cells adapt to these disruptions, making vital enzymes in these pathways attractive candidates for screens identifying synthetic interactions (SI). My objective is to identify growth inhibiting SIs with these vital enzymes (ie. query genes), providing dual targets for supressing growth of various cancer cell types successfully. I will knockout (KO) genes, making them non-functional, and conduct screens where query gene KO cells will be tested in pairwise KOs with every other gene in the genome. Each combination will be analyzed, and those showing significant decreases in cell growth will be identified as SIs. Early results from one query gene KO, NAGK, revealed significant growth restriction in combination with 63 other KOs. Generating these double KOs in many cancer cell lines will validate the SIs that most inhibit cell growth. Where drugs are available for targeting our genes, the drug interactions will be tested and compared to the KO interactions. These SIs will also be tested in cancer mouse models. With on average 565 Canadians diagnosed with cancer every day, better treatment for all cancer types is needed. My project will report novel SIs with anti-cancer activity that will apply across many cancer types.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
386540
Name
Chirila Alexandra
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Using CRISPR/Cas9 knockout systems to identify synthetic interactions with hexosamine biosynthesis and N-glycan remodelling pathway enzymes to inhibit cancer cell growth
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Crispr/Cas9; Hexosamine Biosynthesis Pathway; N-Glycan Remodelling; Synthetic Interactions
Abstract
Cancer research has shifted towards developing therapies that target multiple points of a cell, as cancer cells often adapt to treatment and develop resistance. A method of identifying multiple targets uses synthetic lethal interactions, where mutations of single genes alone are not lethal, but specific mutations together result in cell death. Previous studies on cancer cell metabolism showed that disrupting hexosamine biosynthesis and N-glycan remodelling pathways inhibit tumor growth. Little is known about how cancer cells adapt to these disruptions, making vital enzymes in these pathways attractive candidates for screens identifying synthetic interactions (SI). My objective is to identify growth inhibiting SIs with these vital enzymes (ie. query genes), providing dual targets for supressing growth of various cancer cell types successfully. I will knockout (KO) genes, making them non-functional, and conduct screens where query gene KO cells will be tested in pairwise KOs with every other gene in the genome. Each combination will be analyzed, and those showing significant decreases in cell growth will be identified as SIs. Early results from one query gene KO, NAGK, revealed significant growth restriction in combination with 63 other KOs. Generating these double KOs in many cancer cell lines will validate the SIs that most inhibit cell growth. Where drugs are available for targeting our genes, the drug interactions will be tested and compared to the KO interactions. These SIs will also be tested in cancer mouse models. With on average 565 Canadians diagnosed with cancer every day, better treatment for all cancer types is needed. My project will report novel SIs with anti-cancer activity that will apply across many cancer types.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
Chirila, Alexandra
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~